Ribobio Biotechnology Limited (06938.HK) and its subsidiary, Ribocure Pharmaceuticals AB, have successfully submitted an Investigational New Drug (IND) application for...
-
-
Recent Updates
- Revolutionizing Cancer Immunotherapy with Chinese Nanomedicine Innovations
- LGF Lab Gas Flow Innovates with Ultra-High Purity Systems in Chinese Laboratories
- Rising Tariffs Threaten Momentum of Chinese Electric Cars in the UK
- China’s Balancing Act: Harnessing AI Growth Without Fueling Investment Bubbles
- EU-China Accord Lowers Car Export Threat, Enhances Trade Prospects
- China-EU Agreement on Reduction of Hybrid Vehicle Exports Decisively Concluded
- Challenges and Choices: China’s Impact on Zespri’s Kiwifruit Strategies
- China Allocates $82 Billion to Support Economy Amid Growth Target Challenges
- What’s New in Shanghai, From Restaurants, Retail to Exhibitions
- Birthday boy Shelton and top seed Zverev advance at Shanghai Masters
Blogroll